| Year |
Citation |
Score |
| 2023 |
Gray BP, Kelly L, Steen-Burrell KA, Layzer JM, Rempel RE, Nimjee SM, Cooley BC, Tarantal AF, Sullenger BA. Rapid molecular imaging of active thrombi using aptamer-antidote probes. Molecular Therapy. Nucleic Acids. 31: 440-451. PMID 36817726 DOI: 10.1016/j.omtn.2023.01.009 |
0.552 |
|
| 2022 |
Shea SM, Thomas KA, Rassam RMG, Mihalko EP, Daniel C, Sullenger BA, Spinella PC, Nimjee SM. Dose-Dependent Von Willebrand Factor Inhibition by Aptamer BB-031 Correlates with Thrombolysis in a Microfluidic Model of Arterial Occlusion. Pharmaceuticals (Basel, Switzerland). 15. PMID 36558901 DOI: 10.3390/ph15121450 |
0.572 |
|
| 2022 |
Corey KM, Olson LB, Naqvi IA, Morrison SA, Davis C, Nimjee SM, Que LG, Bachelder RE, Kraft BD, Chen L, Nair SK, Levy JH, Sullenger BA. Exposure and Outcome in practice: a retrospective cohort study between fibrinolytic suppression and hypercoagulability, the severity of hypoxemia, and mortality in COVID-19 patients. Anesthesiology. PMID 35412597 DOI: 10.1097/ALN.0000000000004239 |
0.497 |
|
| 2020 |
Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. Journal of Neurointerventional Surgery. PMID 33298508 DOI: 10.1136/neurintsurg-2020-016794 |
0.507 |
|
| 2020 |
Sullenger BA. RGEN Editing of RNA and DNA: The Long and Winding Road from Catalytic RNAs to CRISPR to the Clinic. Cell. 181: 955-960. PMID 32470403 DOI: 10.1016/J.Cell.2020.04.050 |
0.376 |
|
| 2020 |
Eteshola E, Landa K, Hwang ES, Nair S, Sullenger B. Blocking pro-invasive signaling and inflammatory activation in triple-negative breast cancer with nucleic-acid scavengers (NASs). Journal of Clinical Oncology. 38: e13096-e13096. DOI: 10.1200/Jco.2020.38.15_Suppl.E13096 |
0.338 |
|
| 2020 |
Nair S, Holl E, Landa K, Frazier V, Eteshola E, Boczkowski D, Rempel R, Hwang S, Sullenger B. Abstract P3-01-03: Modulating inflammation with nucleic acid scavengers to prevent breast cancer metastasis Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-01-03 |
0.321 |
|
| 2019 |
Gray BP, Requena MD, Nichols MD, Sullenger BA. Aptamers as Reversible Sorting Ligands for Preparation of Cells in Their Native State. Cell Chemical Biology. PMID 31879266 DOI: 10.1016/J.Chembiol.2019.12.004 |
0.324 |
|
| 2019 |
Nimjee SM, Sullenger BA. Therapeutic Aptamers: Evolving to Find Their Clinical Niche. Current Medicinal Chemistry. PMID 31573879 DOI: 10.2174/0929867326666191001125101 |
0.64 |
|
| 2019 |
Nimjee SM, Dornbos D, Pitoc GA, Wheeler DG, Layzer JM, Venetos N, Huttinger A, Talentino SE, Musgrave NJ, Moody H, Rempel RE, Jones C, Carlisle K, Wilson J, Bratton C, ... ... Sullenger BA, et al. Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 30987839 DOI: 10.1016/J.Ymthe.2019.03.016 |
0.622 |
|
| 2019 |
Moreno A, Pitoc GA, Ganson NJ, Layzer JM, Hershfield MS, Tarantal AF, Sullenger BA. Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers. Cell Chemical Biology. PMID 30827937 DOI: 10.1016/J.Chembiol.2019.02.001 |
0.324 |
|
| 2019 |
Sullenger BA. Aptamers as Rapid Onset and Rapidly Reversible Antithrombotic Agents Blood. 134: SCI-16-SCI-16. DOI: 10.1182/Blood-2019-121056 |
0.392 |
|
| 2018 |
Huttinger AL, Wheeler DG, Gnyawali S, Dornbos D, Layzer JM, Venetos N, Talentino S, Musgrave NJ, Jones C, Bratton C, Joseph ME, Sen C, Sullenger BA, Nimjee SM. Ferric Chloride-induced Canine Carotid Artery Thrombosis: A Large Animal Model of Vascular Injury. Journal of Visualized Experiments : Jove. PMID 30247470 DOI: 10.3791/57981 |
0.566 |
|
| 2018 |
Chabata CV, Frederiksen JW, Sullenger BA, Gunaratne R. Emerging applications of aptamers for anticoagulation and hemostasis. Current Opinion in Hematology. 25: 382-388. PMID 30015643 DOI: 10.1097/Moh.0000000000000452 |
0.389 |
|
| 2018 |
Gunaratne R, Kumar S, Frederiksen JW, Stayrook S, Lohrmann JL, Perry K, Bompiani KM, Chabata CV, Thalji NK, Ho MD, Arepally G, Camire RM, Krishnaswamy S, Sullenger BA. Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass. Nature Biotechnology. PMID 29863725 DOI: 10.1038/Nbt.4153 |
0.789 |
|
| 2018 |
Powell Gray B, Kelly L, Ahrens DP, Barry AP, Kratschmer C, Levy M, Sullenger BA. Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 29666232 DOI: 10.1073/Pnas.1717705115 |
0.325 |
|
| 2018 |
Naqvi I, Gunaratne R, McDade JE, Moreno A, Rempel RE, Rouse DC, Herrera SG, Pisetsky DS, Lee J, White RR, Sullenger BA. Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29550075 DOI: 10.1016/J.Ymthe.2018.02.018 |
0.404 |
|
| 2018 |
LaCroix BL, Patierno BM, Sullenger BA, George DJ, Patierno SR, Freedman JA. Abstract SY45-02: Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7445.Am2018-Sy45-02 |
0.362 |
|
| 2017 |
Woodruff RS, Ivanov I, Verhamme IM, Sun MF, Gailani D, Sullenger BA. Generation and characterization of aptamers targeting factor XIa. Thrombosis Research. 156: 134-141. PMID 28644959 DOI: 10.1016/J.Thromres.2017.06.015 |
0.309 |
|
| 2017 |
Steen Burrell KA, Layzer J, Sullenger BA. A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release. Journal of Thrombosis and Haemostasis : Jth. 15: 1807-1817. PMID 28632925 DOI: 10.1111/Jth.13760 |
0.386 |
|
| 2017 |
Lee J, Lee Y, Xu L, White R, Sullenger BA. Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28372998 DOI: 10.1016/J.Ymthe.2017.03.014 |
0.393 |
|
| 2017 |
Toulmé JJ, Giangrande PH, Mayer G, Suess B, Ducongé F, Sullenger B, de Franciscis V, Darfeuille F, Peyrin E. Aptamers in Bordeaux, 24-25 June 2016. Pharmaceuticals (Basel, Switzerland). 10. PMID 28117671 DOI: 10.3390/Ph10010014 |
0.333 |
|
| 2017 |
Nimjee SM, White RR, Becker RC, Sullenger BA. Aptamers as Therapeutics. Annual Review of Pharmacology and Toxicology. 57: 61-79. PMID 28061688 DOI: 10.1146/Annurev-Pharmtox-010716-104558 |
0.644 |
|
| 2017 |
Freedman JA, Robinson T, LaCroix B, Patierno B, George D, Sullenger B, Patierno S. Abstract 1232: Development of novel therapeutic splice-switching oligonucleotides targeting oncogenic RNA isoforms driving race-related aggressive prostate cancer Cancer Research. 77: 1232-1232. DOI: 10.1158/1538-7445.Am2017-1232 |
0.381 |
|
| 2016 |
Jackman JG, Juwarker H, Poveromo LP, Levinson H, Leong KW, Sullenger BA. Polycationic Nanofibers for Nucleic Acid Scavenging. Biomacromolecules. PMID 27741396 DOI: 10.1021/Acs.Biomac.6B01236 |
0.324 |
|
| 2016 |
Lee J, Xu L, Gibson TM, Gersbach CA, Sullenger BA. Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts. Biochemical and Biophysical Research Communications. PMID 27586271 DOI: 10.1016/J.Bbrc.2016.08.159 |
0.312 |
|
| 2016 |
Holl EK, Shumansky KL, Borst LB, Burnette AD, Sample CJ, Ramsburg EA, Sullenger BA. Scavenging nucleic acid debris to combat autoimmunity and infectious disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 27528673 DOI: 10.1073/Pnas.1607011113 |
0.313 |
|
| 2016 |
Kahsai AW, Wisler JW, Lee J, Ahn S, Cahill Iii TJ, Dennison SM, Staus DP, Thomsen AR, Anasti KM, Pani B, Wingler LM, Desai H, Bompiani KM, Strachan RT, Qin X, ... ... Sullenger BA, et al. Conformationally selective RNA aptamers allosterically modulate the β2-adrenoceptor. Nature Chemical Biology. PMID 27398998 DOI: 10.1038/Nchembio.2126 |
0.783 |
|
| 2016 |
Sullenger BA, Nair S. From the RNA world to the clinic. Science (New York, N.Y.). 352: 1417-20. PMID 27313039 DOI: 10.1126/Science.Aad8709 |
0.397 |
|
| 2016 |
Mi J, Ray P, Liu J, Kuan CT, Xu J, Hsu D, Sullenger BA, White RR, Clary BM. In Vivo Selection Against Human Colorectal Cancer Xenografts Identifies an Aptamer That Targets RNA Helicase Protein DHX9. Molecular Therapy. Nucleic Acids. 5: e315. PMID 27115840 DOI: 10.1038/Mtna.2016.27 |
0.617 |
|
| 2016 |
Nimjee SM, Povsic TJ, Sullenger BA, Becker RC. Translation and Clinical Development of Antithrombotic Aptamers. Nucleic Acid Therapeutics. PMID 26882082 DOI: 10.1089/Nat.2015.0581 |
0.625 |
|
| 2016 |
Lee Y, Urban JH, Xu L, Sullenger BA, Lee J. 2'Fluoro Modification Differentially Modulates the Ability of RNAs to Activate Pattern Recognition Receptors. Nucleic Acid Therapeutics. PMID 26789413 DOI: 10.1089/Nat.2015.0575 |
0.811 |
|
| 2016 |
Plautz WE, Layzer J, Sullenger BA, Majumder R. Aptamer Mediated Inhibition of Protein S Blood. 128: 4946-4946. DOI: 10.1182/Blood.V128.22.4946.4946 |
0.395 |
|
| 2016 |
Gunaratne R, Frederiksen J, Thalji NK, Ho MD, Arepally GM, Camire RM, Sullenger BA. RNA Aptamer Against FXa Synergizes with FXa Catalytic Site Inhibitors to Effectively and Reversibly Anticoagulate Blood in an Ex Vivo Oxygenator Circuit Blood. 128: 3823-3823. DOI: 10.1182/Blood.V128.22.3823.3823 |
0.372 |
|
| 2016 |
Freedman JA, Robinson TJ, LaCroix B, Patierno BM, George DJ, Sullenger BA, Patierno SR. Abstract B18: Development of novel therapeutic splice-switching oligonucleotides against aggressive prostate cancer in men of African descent Cancer Epidemiology, Biomarkers & Prevention. 25. DOI: 10.1158/1538-7755.Disp15-B18 |
0.349 |
|
| 2015 |
Ganson NJ, Povsic TJ, Sullenger BA, Alexander JH, Zelenkofske SL, Sailstad JM, Rusconi CP, Hershfield MS. Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. The Journal of Allergy and Clinical Immunology. PMID 26688515 DOI: 10.1016/J.Jaci.2015.10.034 |
0.313 |
|
| 2015 |
Soule EE, Bompiani KM, Woodruff RS, Sullenger BA. Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant. Nucleic Acid Therapeutics. PMID 26584417 DOI: 10.1089/nat.2015.0565 |
0.787 |
|
| 2015 |
Woodruff RS, Sullenger BA. Modulation of the Coagulation Cascade Using Aptamers. Arteriosclerosis, Thrombosis, and Vascular Biology. 35: 2083-91. PMID 26315404 DOI: 10.1161/Atvbaha.115.300131 |
0.433 |
|
| 2015 |
Pratico ED, Feger BJ, Watson MJ, Sullenger BA, Bowles DE, Milano CA, Nair S. RNA-mediated reprogramming of primary adult human dermal fibroblasts into c-kit+ cardiac progenitor cells. Stem Cells and Development. PMID 26176491 DOI: 10.1089/scd.2015.0073 |
0.769 |
|
| 2015 |
Gray BP, Kelly L, Levy M, Sullenger BA. Abstract 5523: A novel aptamer targeting agent for prostate cancer Cancer Research. 75: 5523-5523. DOI: 10.1158/1538-7445.Am2015-5523 |
0.357 |
|
| 2015 |
Jackman JG, Juwarker H, Bashirov L, Leong K, Levinson H, Sullenger B. 272. Nucleic Acid Scavenging Nanofibers as Anti-Inflammatory Meshes Molecular Therapy. 23: S108-S109. DOI: 10.1016/S1525-0016(16)33881-3 |
0.329 |
|
| 2015 |
Pratico ED, Nair SK, Sullenger BA. 66. Identification and Characterization of a B Cell Aptamer That Targets Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Myelogenous Leukemia (CML) Molecular Therapy. 23: S29. DOI: 10.1016/S1525-0016(16)33671-1 |
0.803 |
|
| 2015 |
Powell Gray B, Kelly L, Levy M, Sullenger BA. 65. A Novel Aptamer Targeting Agent for Prostate Cancer Molecular Therapy. 23: S28-S29. DOI: 10.1016/S1525-0016(16)33670-X |
0.355 |
|
| 2014 |
Bompiani KM, Lohrmann JL, Pitoc GA, Frederiksen JW, Mackensen GB, Sullenger BA. Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation. Chemistry & Biology. 21: 935-44. PMID 25065530 DOI: 10.1016/J.Chembiol.2014.05.016 |
0.779 |
|
| 2014 |
Kotula JW, Sun J, Li M, Pratico ED, Fereshteh MP, Ahrens DP, Sullenger BA, Kovacs JJ. Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth. Plos One. 9: e93441. PMID 24736311 DOI: 10.1371/Journal.Pone.0093441 |
0.78 |
|
| 2014 |
Lewis DA, Nimjee SM, Pitoc GA, Khan S, Becker RC, Sullenger BA, Ortel TL. Laboratory Assessment of Anti-Coagulant Properties of a Von Willebrand Factor Targeted Aptamer Blood. 124: 4279-4279. DOI: 10.1182/Blood.V124.21.4279.4279 |
0.613 |
|
| 2014 |
Kumar S, Sullenger BA, Stayrook S, Krishnaswamy S. X-Ray Structure of an Anticoagulant RNA Aptamer Bound to Factor Xa. Structural Basis for Its Ability to Disrupt Interactions Between Xa and Va within Prothrombinase Blood. 124: 4232-4232. DOI: 10.1182/Blood.V124.21.4232.4232 |
0.355 |
|
| 2014 |
Lee J, Lee Y, Sullenger BA. Abstract 2639: Development of immunocytotoxic RNA therapeutics for human melanoma Cancer Research. 74: 2639-2639. DOI: 10.1158/1538-7445.Am2014-2639 |
0.438 |
|
| 2013 |
Ray P, Sullenger BA, White RR. Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications. Nucleic Acid Therapeutics. 23: 435-42. PMID 24152208 DOI: 10.1089/Nat.2013.0439 |
0.535 |
|
| 2013 |
Holl EK, Shumansky KL, Pitoc G, Ramsburg E, Sullenger BA. Nucleic acid scavenging polymers inhibit extracellular DNA-mediated innate immune activation without inhibiting anti-viral responses. Plos One. 8: e69413. PMID 23936008 DOI: 10.1371/Journal.Pone.0069413 |
0.319 |
|
| 2013 |
Woodruff RS, Xu Y, Layzer J, Wu W, Ogletree ML, Sullenger BA. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. Journal of Thrombosis and Haemostasis : Jth. 11: 1364-73. PMID 23692437 DOI: 10.1111/Jth.12302 |
0.379 |
|
| 2013 |
Pratico ED, Sullenger BA, Nair SK. Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40. Nucleic Acid Therapeutics. 23: 35-43. PMID 23113766 DOI: 10.1089/Nat.2012.0388 |
0.789 |
|
| 2013 |
Krishnan A, Vogler EA, Sullenger BA, Becker RC. The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa. Journal of Thrombosis and Thrombolysis. 35: 48-56. PMID 23054460 DOI: 10.1007/S11239-012-0778-7 |
0.37 |
|
| 2012 |
Ray P, Cheek MA, Sharaf ML, Li N, Ellington AD, Sullenger BA, Shaw BR, White RR. Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. Nucleic Acid Therapeutics. 22: 295-305. PMID 23030589 DOI: 10.1089/Nat.2012.0353 |
0.581 |
|
| 2012 |
Jain S, Pitoc GA, Holl EK, Zhang Y, Borst L, Leong KW, Lee J, Sullenger BA. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proceedings of the National Academy of Sciences of the United States of America. 109: 12938-43. PMID 22837404 DOI: 10.1073/Pnas.1204928109 |
0.402 |
|
| 2012 |
Stearns NA, Lee J, Leong KW, Sullenger BA, Pisetsky DS. The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers. Plos One. 7: e40862. PMID 22808279 DOI: 10.1371/Journal.Pone.0040862 |
0.302 |
|
| 2012 |
Kotula JW, Pratico ED, Ming X, Nakagawa O, Juliano RL, Sullenger BA. Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Therapeutics. 22: 187-95. PMID 22703281 DOI: 10.1089/Nat.2012.0347 |
0.792 |
|
| 2012 |
Ray P, Rialon-Guevara KL, Veras E, Sullenger BA, White RR. Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. The Journal of Clinical Investigation. 122: 1734-41. PMID 22484812 DOI: 10.1172/Jci62385 |
0.536 |
|
| 2012 |
Wang J, Sullenger BA, Rich JN. Notch signaling in cancer stem cells. Advances in Experimental Medicine and Biology. 727: 174-85. PMID 22399347 DOI: 10.1007/978-1-4614-0899-4_13 |
0.312 |
|
| 2012 |
Bompiani KM, Monroe DM, Church FC, Sullenger BA. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. Journal of Thrombosis and Haemostasis : Jth. 10: 870-80. PMID 22385910 DOI: 10.1111/J.1538-7836.2012.04679.X |
0.805 |
|
| 2012 |
Bompiani KM, Woodruff RS, Becker RC, Nimjee SM, Sullenger BA. Antidote control of aptamer therapeutics: the road to a safer class of drug agents. Current Pharmaceutical Biotechnology. 13: 1924-34. PMID 22352726 DOI: 10.2174/138920112802273137 |
0.8 |
|
| 2012 |
Sullenger B, Woodruff R, Monroe DM. Potent anticoagulant aptamer directed against factor IXa blocks macromolecular substrate interaction. The Journal of Biological Chemistry. 287: 12779-86. PMID 22334679 DOI: 10.1074/Jbc.M111.300772 |
0.361 |
|
| 2012 |
Nimjee SM, Lohrmann JD, Wang H, Snyder DJ, Cummings TJ, Becker RC, Oney S, Sullenger BA. Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 391-7. PMID 22086230 DOI: 10.1038/Mt.2011.226 |
0.787 |
|
| 2012 |
Rangnekar A, Zhang AM, Li SS, Bompiani KM, Hansen MN, Gothelf KV, Sullenger BA, LaBean TH. Increased anticoagulant activity of thrombin-binding DNA aptamers by nanoscale organization on DNA nanostructures. Nanomedicine : Nanotechnology, Biology, and Medicine. 8: 673-81. PMID 21889476 DOI: 10.1016/J.Nano.2011.08.011 |
0.764 |
|
| 2012 |
Rialon K, Viles K, Barbas A, Sullenger B, White R. In Vivo Selection of Aptamers Targeting Pancreatic Cancer Journal of Surgical Research. 172: 341. DOI: 10.1016/J.Jss.2011.11.709 |
0.781 |
|
| 2011 |
Brandal S, Blake CM, Sullenger BA, Fortenberry YM. Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation. Nucleic Acid Therapeutics. 21: 373-81. PMID 22103403 DOI: 10.1089/Nat.2011.0320 |
0.778 |
|
| 2011 |
Lee J, Sohn JW, Zhang Y, Leong KW, Pisetsky D, Sullenger BA. Nucleic acid-binding polymers as anti-inflammatory agents. Proceedings of the National Academy of Sciences of the United States of America. 108: 14055-60. PMID 21844380 DOI: 10.1073/Pnas.1105777108 |
0.32 |
|
| 2011 |
Burnette AD, Nimjee SM, Batchvarova M, Zennadi R, Telen MJ, Nishimura J, Sullenger BA. RNA aptamer therapy for vaso-occlusion in sickle cell disease. Nucleic Acid Therapeutics. 21: 275-83. PMID 21793788 DOI: 10.1089/Nat.2010.0270 |
0.628 |
|
| 2011 |
Woodruff RS, Sullenger B, Becker RC. The many faces of the contact pathway and their role in thrombosis. Journal of Thrombosis and Thrombolysis. 32: 9-20. PMID 21404067 DOI: 10.1007/S11239-011-0578-5 |
0.303 |
|
| 2011 |
Blake CM, Wang H, Laskowitz DT, Sullenger BA. A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage. Oligonucleotides. 21: 11-9. PMID 21142878 DOI: 10.1089/Oli.2010.0262 |
0.732 |
|
| 2011 |
Ray P, Sullenger BA, White RR. Abstract 2817: An RNA aptamer is a potential biomarker for pancreatic cancer Cancer Research. 71: 2817-2817. DOI: 10.1158/1538-7445.Am2011-2817 |
0.582 |
|
| 2011 |
Barbas A, Viles K, Rialon K, Mi J, Clary B, Sullenger B, White R. In-vivo SELEX Against Pancreatic Cancer Xenografts Journal of Surgical Research. 165: 307. DOI: 10.1016/J.Jss.2010.11.362 |
0.76 |
|
| 2010 |
Povsic TJ, Sullenger BA, Zelenkofske SL, Rusconi CP, Becker RC. Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine. Journal of Cardiovascular Translational Research. 3: 704-16. PMID 21080135 DOI: 10.1007/S12265-010-9230-6 |
0.432 |
|
| 2010 |
Becker RC, Povsic T, Cohen MG, Rusconi CP, Sullenger B. Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics Thrombosis and Haemostasis. 103: 586-595. PMID 20135076 DOI: 10.1160/Th09-10-0716 |
0.347 |
|
| 2010 |
Buddai SK, Layzer JM, Lu G, Rusconi CP, Sullenger BA, Monroe DM, Krishnaswamy S. An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase. The Journal of Biological Chemistry. 285: 5212-23. PMID 20022942 DOI: 10.1074/Jbc.M109.049833 |
0.401 |
|
| 2010 |
Mi J, Liu Y, Rabbani ZN, Yang Z, Urban JH, Sullenger BA, Clary BM. In vivo selection of tumor-targeting RNA motifs. Nature Chemical Biology. 6: 22-4. PMID 19946274 DOI: 10.1038/Nchembio.277 |
0.813 |
|
| 2010 |
Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich JN, Sullenger BA. Notch promotes radioresistance of glioma stem cells. Stem Cells (Dayton, Ohio). 28: 17-28. PMID 19921751 DOI: 10.1002/Stem.261 |
0.302 |
|
| 2009 |
Nimjee SM, Oney S, Volovyk Z, Bompiani KM, Long SB, Hoffman M, Sullenger BA. Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. Rna (New York, N.Y.). 15: 2105-11. PMID 19846574 DOI: 10.1261/Rna.1240109 |
0.799 |
|
| 2009 |
Oney S, Lam RT, Bompiani KM, Blake CM, Quick G, Heidel JD, Liu JY, Mack BC, Davis ME, Leong KW, Sullenger BA. Development of universal antidotes to control aptamer activity. Nature Medicine. 15: 1224-8. PMID 19801990 DOI: 10.1038/Nm.1990 |
0.782 |
|
| 2009 |
Becker RC, Oney S, Becker KC, Sullenger B. Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor. Annals of the New York Academy of Sciences. 1175: 61-70. PMID 19796078 DOI: 10.1111/J.1749-6632.2009.05017.X |
0.731 |
|
| 2009 |
Zhou J, Soontornworajit B, Martin J, Sullenger BA, Gilboa E, Wang Y. A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling. Macromolecular Bioscience. 9: 831-5. PMID 19434675 DOI: 10.1002/Mabi.200900046 |
0.386 |
|
| 2009 |
Blake CM, Sullenger BA, Lawrence DA, Fortenberry YM. Antimetastatic potential of PAI-1-specific RNA aptamers. Oligonucleotides. 19: 117-28. PMID 19284310 DOI: 10.1089/Oli.2008.0177 |
0.769 |
|
| 2009 |
Liu Y, Sun QA, Chen Q, Lee TH, Huang Y, Wetsel WC, Michelotti GA, Sullenger BA, Zhang X. Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking. Journal of Neurochemistry. 108: 147-57. PMID 19046328 DOI: 10.1111/J.1471-4159.2008.05748.X |
0.319 |
|
| 2009 |
Liu Y, Kuan CT, Mi J, Zhang X, Clary BM, Bigner DD, Sullenger BA. Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biological Chemistry. 390: 137-44. PMID 19040357 DOI: 10.1515/Bc.2009.022 |
0.4 |
|
| 2009 |
Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 153-61. PMID 18985031 DOI: 10.1038/Mt.2008.235 |
0.426 |
|
| 2009 |
Nimjee S, Sullenger B. Aptamers in the clinic Drugs of the Future. 34: 897. DOI: 10.1358/Dof.2009.034.11.1445907 |
0.56 |
|
| 2009 |
Fortenberry Y, Blake CM, Sullenger BA. Effect of PAI-1 Specific RNA Aptamers On Cell Adhesion and Motility. Blood. 114: 2135-2135. DOI: 10.1182/Blood.V114.22.2135.2135 |
0.795 |
|
| 2009 |
Mi J, Liu Y, Rabbani Z, Yang Z, Sullenger B, Clary B. 184. In Vivo SELEX: Generation of Aptamers and Identification of Target Protein Relevant to Tumor Journal of Surgical Research. 151: 256. DOI: 10.1016/J.Jss.2008.11.223 |
0.315 |
|
| 2008 |
White RR, Roy JA, Viles KD, Sullenger BA, Kontos CD. A nuclease-resistant RNA aptamer specifically inhibits angiopoietin-1-mediated Tie2 activation and function. Angiogenesis. 11: 395-401. PMID 19037734 DOI: 10.1007/S10456-008-9122-4 |
0.786 |
|
| 2008 |
Long SB, Long MB, White RR, Sullenger BA. Crystal structure of an RNA aptamer bound to thrombin. Rna (New York, N.Y.). 14: 2504-12. PMID 18971322 DOI: 10.1261/Rna.1239308 |
0.656 |
|
| 2008 |
Dollins CM, Nair S, Boczkowski D, Lee J, Layzer JM, Gilboa E, Sullenger BA. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chemistry & Biology. 15: 675-82. PMID 18635004 DOI: 10.1016/J.Chembiol.2008.05.016 |
0.783 |
|
| 2008 |
Dollins CM, Nair S, Sullenger BA. Aptamers in immunotherapy. Human Gene Therapy. 19: 443-50. PMID 18473674 DOI: 10.1089/Hum.2008.045 |
0.795 |
|
| 2008 |
Viles KD, Sullenger BA. Proximity-dependent and proximity-independent trans-splicing in mammalian cells. Rna (New York, N.Y.). 14: 1081-94. PMID 18441053 DOI: 10.1261/Rna.384808 |
0.779 |
|
| 2008 |
Lee J, Dollins CM, Boczkowski D, Sullenger BA, Nair S. Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology. 125: 229-40. PMID 18393968 DOI: 10.1111/J.1365-2567.2008.02833.X |
0.782 |
|
| 2008 |
McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH, Sullenger B, Gilboa E. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. The Journal of Clinical Investigation. 118: 376-86. PMID 18060045 DOI: 10.1172/Jci33365 |
0.384 |
|
| 2008 |
Sarraf-Yazdi S, Mi J, Moeller BJ, Niu X, White RR, Kontos CD, Sullenger BA, Dewhirst MW, Clary BM. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. The Journal of Surgical Research. 146: 16-23. PMID 17950331 DOI: 10.1016/J.Jss.2007.04.028 |
0.365 |
|
| 2008 |
Mi J, Zhang X, Rabbani ZN, Liu Y, Reddy SK, Su Z, Salahuddin FK, Viles K, Giangrande PH, Dewhirst MW, Sullenger BA, Kontos CD, Clary BM. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 66-73. PMID 17912235 DOI: 10.1038/Sj.Mt.6300320 |
0.793 |
|
| 2008 |
Hong SH, Jeong JS, Lee YJ, Jung HI, Cho KS, Kim CM, Kwon BS, Sullenger BA, Lee SW, Kim IH. In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 74-80. PMID 17700543 DOI: 10.1038/Sj.Mt.6300282 |
0.407 |
|
| 2008 |
Blake CM, Oney S, Nimjee SM, Sullenger BA. Aptamers and siRNAs in cardiovascular disease Rna Technologies in Cardiovascular Medicine and Research. 255-287. DOI: 10.1007/978-3-540-78709-9_13 |
0.788 |
|
| 2007 |
Oney S, Nimjee SM, Layzer J, Que-Gewirth N, Ginsburg D, Becker RC, Arepally G, Sullenger BA. Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides. 17: 265-74. PMID 17854267 DOI: 10.1089/Oli.2007.0089 |
0.797 |
|
| 2007 |
Giangrande PH, Zhang J, Tanner A, Eckhart AD, Rempel RE, Andrechek ER, Layzer JM, Keys JR, Hagen PO, Nevins JR, Koch WJ, Sullenger BA. Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proceedings of the National Academy of Sciences of the United States of America. 104: 12988-93. PMID 17652516 DOI: 10.1073/Pnas.0704754104 |
0.784 |
|
| 2007 |
Mi J, Zhang X, Liu Y, Reddy SK, Rabbani ZN, Sullenger BA, Clary BM. NF-kappaB inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis. Biochemical and Biophysical Research Communications. 359: 475-80. PMID 17560552 DOI: 10.1016/J.Bbrc.2007.05.125 |
0.345 |
|
| 2007 |
Kierlin-Duncan MN, Sullenger BA. Using 5'-PTMs to repair mutant beta-globin transcripts. Rna (New York, N.Y.). 13: 1317-27. PMID 17556711 DOI: 10.1261/Rna.525607 |
0.773 |
|
| 2007 |
Layzer JM, Sullenger BA. Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. Oligonucleotides. 17: 1-11. PMID 17461758 DOI: 10.1089/Oli.2006.0059 |
0.35 |
|
| 2007 |
Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Therapy. 14: 283-91. PMID 17279100 DOI: 10.1038/Sj.Gt.3302900 |
0.44 |
|
| 2007 |
Nishimura J, Telen MJ, Sullenger BA. Innovative Drug Design Using RNA Aptamers for Various Anaemias Oral History Review. 2: 55. DOI: 10.17925/Ohr.2007.01.01.55 |
0.341 |
|
| 2007 |
Nishimura J, Burnette AD, Oney S, Batchvarova M, Delahunty M, Zennadi R, Sullenger BA, Telen MJ. Blocking Adhesion of Sickle Erythrocytes to Endothelial P-Selectin Using an RNA Aptamer. Blood. 110: 147-147. DOI: 10.1182/Blood.V110.11.147.147 |
0.751 |
|
| 2007 |
Blake C, Wang H, Laskowitz D, Sullenger B. ANTIDOTE REVERSAL OF A NOVEL ANTICOAGULANT DECREASES MORTALITY AND IMPROVES NEUROLOGICAL FUNCTION IN A MURINE MODEL OF SUBARACHNOID HEMORRHAGE Journal of Thrombosis and Haemostasis. 5: O-W-005-O-W-005. DOI: 10.1111/J.1538-7836.2007.Tb02469.X |
0.718 |
|
| 2006 |
Mi J, Zhang X, Rabbani ZN, Liu Y, Su Z, Vujaskovic Z, Kontos CD, Sullenger BA, Clary BM. H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity. Nucleic Acids Research. 34: 3577-84. PMID 16855294 DOI: 10.1093/Nar/Gkl482 |
0.46 |
|
| 2006 |
McNamara JO, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nature Biotechnology. 24: 1005-15. PMID 16823371 DOI: 10.1038/Nbt1223 |
0.821 |
|
| 2006 |
Nimjee SM, Keys JR, Pitoc GA, Quick G, Rusconi CP, Sullenger BA. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Molecular Therapy : the Journal of the American Society of Gene Therapy. 14: 408-15. PMID 16765093 DOI: 10.1016/J.Ymthe.2006.04.006 |
0.607 |
|
| 2006 |
Nishimura J, Burnette AD, Batchvarova M, Nimjee SM, Zennadi R, Sullenger BA, Telen MJ. Blocking Adhesion of Sickle Erythrocytes to Endothelial αVβ3 Using RNA Aptamer. Blood. 108: 688-688. DOI: 10.1182/Blood.V108.11.688.688 |
0.657 |
|
| 2006 |
Catron DJ, Giangrande PH, Sullenger BA. 1028. Use of Antisense Oligonucleotides To Restore Activity in Mutant p53 Molecular Therapy. 13: S395. DOI: 10.1016/J.Ymthe.2006.08.1123 |
0.355 |
|
| 2006 |
Nimjee SM, Rusconi CP, Sullenger BA. Aptamers to Proteins The Aptamer Handbook: Functional Oligonucleotides and Their Applications. 131-166. DOI: 10.1002/3527608192.ch6 |
0.516 |
|
| 2005 |
Mi J, Zhang X, Giangrande PH, McNamara JO, Nimjee SM, Sarraf-Yazdi S, Sullenger BA, Clary BM. Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochemical and Biophysical Research Communications. 338: 956-63. PMID 16256939 DOI: 10.1016/J.Bbrc.2005.10.043 |
0.666 |
|
| 2005 |
Becker RC, Rusconi C, Sullenger B. Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. Thrombosis and Haemostasis. 93: 1014-20. PMID 15968382 DOI: 10.1160/Th04-12-0790 |
0.323 |
|
| 2005 |
Nimjee SM, Rusconi CP, Harrington RA, Sullenger BA. The potential of aptamers as anticoagulants. Trends in Cardiovascular Medicine. 15: 41-5. PMID 15795162 DOI: 10.1016/J.Tcm.2005.01.002 |
0.626 |
|
| 2005 |
Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. Annual Review of Medicine. 56: 555-83. PMID 15660527 DOI: 10.1146/Annurev.Med.56.062904.144915 |
0.644 |
|
| 2005 |
Nishimura J, Nimjee SM, Jiang H, Howard TA, Pitoc GA, Rusconi CP, Omine M, Chao NJ, Frank MM, Sullenger BA, Ware RE. Blocking Complement-Mediated Hemolysis Using RNA Aptamers That Bind Complement Component C8. Blood. 106: 186-186. DOI: 10.1182/Blood.V106.11.186.186 |
0.611 |
|
| 2005 |
Giangrande PH, Zhang J, Layzer J, Hagen O, Nevins JR, Sullenger BA. 377. Developing siRNAs to the E2Fs to Control Vascular Growth and Remodeling Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.380 |
0.331 |
|
| 2004 |
Sullenger BA. Riboswitches--to kill or save the messenger. The New England Journal of Medicine. 351: 2759-60. PMID 15616213 DOI: 10.1056/Nejmcibr043522 |
0.315 |
|
| 2004 |
Rusconi CP, Roberts JD, Pitoc GA, Nimjee SM, White RR, Quick G, Scardino E, Fay WP, Sullenger BA. Antidote-mediated control of an anticoagulant aptamer in vivo. Nature Biotechnology. 22: 1423-8. PMID 15502817 DOI: 10.1038/Nbt1023 |
0.587 |
|
| 2004 |
Potti A, Rusconi CP, Sullenger BA, Ortel TL. Regulatable aptamers in medicine: focus on antithrombotic strategies. Expert Opinion On Biological Therapy. 4: 1641-7. PMID 15461575 DOI: 10.1517/14712598.4.10.1641 |
0.365 |
|
| 2004 |
Shin KS, Sullenger BA, Lee SW. Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 365-72. PMID 15294183 DOI: 10.1016/J.Ymthe.2004.05.007 |
0.407 |
|
| 2004 |
Jeter ML, Ly LV, Fortenberry YM, Whinna HC, White RR, Rusconi CP, Sullenger BA, Church FC. RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. Febs Letters. 568: 10-4. PMID 15196911 DOI: 10.1016/J.Febslet.2004.04.087 |
0.401 |
|
| 2004 |
Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs. Rna (New York, N.Y.). 10: 766-71. PMID 15100431 DOI: 10.1261/Rna.5239604 |
0.783 |
|
| 2004 |
Nishimura J, Nimjee S, Jiang H, Kawaguchi T, Nakakuma H, Omine M, Frank MM, Ware RE, Sullenger BA. Blocking Complement-Mediated Hemolysis of PNH Erythrocytes by RNA Aptamers to C8 and C9. Blood. 104: 2824-2824. DOI: 10.1182/Blood.V104.11.2824.2824 |
0.615 |
|
| 2004 |
Kierlin MN, Byun J, Lan N, Long M, Sullenger B. 903. Group I Ribozymes and SMaRT|[trade]| as Trans-Splicing RNA Repair Therapies for |[beta]|-Globin Mutations Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.809 |
0.738 |
|
| 2004 |
Catron DJ, Watanabe T, Shin K, Toloza EM, Lee S, Sullenger BA. 611. Group I intron-mediated trans-splicing revision of mutant p53 RNA transcripts Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.535 |
0.363 |
|
| 2004 |
Tanner AK, Nevins J, Sullenger B. 202. Using RNA to Inhibit Intimal Hperplasia by Blocking E2F Function Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.112 |
0.802 |
|
| 2003 |
Nimjee SM, Sullenger BA. The Sabiston vision of basic science in a department of surgery. Annals of Surgery. 238: S28-32. PMID 14703741 DOI: 10.1097/01.Sla.0000097106.09512.Ab |
0.533 |
|
| 2003 |
Byun J, Lan N, Long M, Sullenger BA. Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes. Rna (New York, N.Y.). 9: 1254-63. PMID 13130139 DOI: 10.1261/Rna.5450203 |
0.718 |
|
| 2003 |
Long MB, Jones JP, Sullenger BA, Byun J. Ribozyme-mediated revision of RNA and DNA. The Journal of Clinical Investigation. 112: 312-8. PMID 12897196 DOI: 10.1172/Jci19386 |
0.645 |
|
| 2003 |
Sullenger BA. Targeted genetic repair: an emerging approach to genetic therapy. The Journal of Clinical Investigation. 112: 310-1. PMID 12897195 DOI: 10.1172/Jci19419 |
0.35 |
|
| 2003 |
White RR, Shan S, Rusconi CP, Shetty G, Dewhirst MW, Kontos CD, Sullenger BA. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proceedings of the National Academy of Sciences of the United States of America. 100: 5028-33. PMID 12692304 DOI: 10.1073/Pnas.0831159100 |
0.391 |
|
| 2002 |
Rogers CS, Vanoye CG, Sullenger BA, George AL. Functional repair of a mutant chloride channel using a trans-splicing ribozyme. The Journal of Clinical Investigation. 110: 1783-9. PMID 12488428 DOI: 10.1172/Jci200216481 |
0.4 |
|
| 2002 |
Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D, Sullenger BA. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature. 419: 90-4. PMID 12214238 DOI: 10.1038/Nature00963 |
0.376 |
|
| 2002 |
Sullenger BA, Gilboa E. Emerging clinical applications of RNA. Nature. 418: 252-8. PMID 12110902 DOI: 10.1038/418252A |
0.372 |
|
| 2002 |
Martell RE, Nevins JR, Sullenger BA. Optimizing aptamer activity for gene therapy applications using expression cassette SELEX. Molecular Therapy : the Journal of the American Society of Gene Therapy. 6: 30-4. PMID 12095300 DOI: 10.1006/Mthe.2002.0624 |
0.448 |
|
| 2002 |
White R, Rusconi C, Scardino E, Wolberg A, Lawson J, Hoffman M, Sullenger B. Generation of species cross-reactive aptamers using "toggle" SELEX. Molecular Therapy : the Journal of the American Society of Gene Therapy. 4: 567-73. PMID 11735341 DOI: 10.1006/Mthe.2001.0495 |
0.396 |
|
| 2000 |
White RR, Sullenger BA, Rusconi CP. Developing aptamers into therapeutics. The Journal of Clinical Investigation. 106: 929-34. PMID 11032851 DOI: 10.1172/Jci11325 |
0.426 |
|
| 2000 |
Sullenger BA. Series introduction: emerging clinical applications of nucleic acids Journal of Clinical Investigation. 106: 921-922. PMID 11032849 DOI: 10.1172/Jci11343 |
0.376 |
|
| 2000 |
Lan N, Rooney BL, Lee SW, Howrey RP, Smith CA, Sullenger BA. Enhancing RNA repair efficiency by combining trans-splicing ribozymes that recognize different accessible sites on a target RNA. Molecular Therapy : the Journal of the American Society of Gene Therapy. 2: 245-55. PMID 10985955 DOI: 10.1006/Mthe.2000.0125 |
0.615 |
|
| 2000 |
Guo H, Karberg M, Long M, Jones JP, Sullenger B, Lambowitz AM. Group II introns designed to insert into therapeutically relevant DNA target sites in human cells. Science (New York, N.Y.). 289: 452-7. PMID 10903206 DOI: 10.1126/Science.289.5478.452 |
0.624 |
|
| 2000 |
Watanabe T, Sullenger BA. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proceedings of the National Academy of Sciences of the United States of America. 97: 8490-4. PMID 10890910 DOI: 10.1073/Pnas.150104097 |
0.321 |
|
| 2000 |
Howrey RP, El-Alfondi M, Phillips KL, Wilson L, Rooney B, Lan N, Sullenger B, Smith C. An in vitro system for efficiently evaluating gene therapy approaches to hemoglobinopathies. Gene Therapy. 7: 215-23. PMID 10694798 DOI: 10.1038/Sj.Gt.3301064 |
0.553 |
|
| 2000 |
Lyerly H, Lawson J, Rusconi C, Yeh A, Sullenger B. Blocking the Initiation of Coagulation by RNA Aptamers to Factor VIIa Thrombosis and Haemostasis. 84: 841-848. DOI: 10.1055/S-0037-1614126 |
0.392 |
|
| 2000 |
White R, Rusconi C, Hoffman M, Lawson J, Sullenger B. Inhibition of human and pig thrombin by a high-affinity nuclease-resistant RNA aptamer Journal of the American College of Surgeons. 191: S74-S75. DOI: 10.1016/S1072-7515(00)00605-0 |
0.375 |
|
| 1999 |
Long MB, Sullenger BA. Evaluating group I intron catalytic efficiency in mammalian cells. Molecular and Cellular Biology. 19: 6479-87. PMID 10490588 DOI: 10.1128/Mcb.19.10.6479 |
0.638 |
|
| 1999 |
Sullenger BA. RNA repair as a novel to genetic therapy Gene Therapy. 6: 461-462. PMID 10476204 DOI: 10.1038/Sj.Gt.3300903 |
0.335 |
|
| 1999 |
Zarrinkar PP, Sullenger BA. Optimizing the substrate specificity of a group I intron ribozyme. Biochemistry. 38: 3426-32. PMID 10079089 DOI: 10.1021/Bi982688M |
0.382 |
|
| 1999 |
Zarrinkar PP, Sullenger BA. Probing the interplay between the two steps of group I intron splicing: competition of exogenous guanosine with omega G. Biochemistry. 37: 18056-63. PMID 9922174 DOI: 10.1021/Bi982193X |
0.354 |
|
| 1998 |
Lan N, Howrey RP, Lee SW, Smith CA, Sullenger BA. Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors. Science (New York, N.Y.). 280: 1593-6. PMID 9616120 DOI: 10.1126/Science.280.5369.1593 |
0.594 |
|
| 1998 |
Sullenger BA. Revising messages traveling along the cellular information superhighway. Chemistry & Biology. 2: 249-53. PMID 9383426 DOI: 10.1016/1074-5521(95)90043-8 |
0.339 |
|
| 1997 |
Jones JT, Sullenger BA. Evaluating and enhancing ribozyme reaction efficiency in mammalian cells Nature Biotechnology. 15: 902-905. PMID 9306408 DOI: 10.1038/Nbt0997-902 |
0.419 |
|
| 1997 |
Lee S, Sullenger BA. Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies Nature Biotechnology. 15: 41-45. PMID 9035104 DOI: 10.1038/Nbt0197-41 |
0.366 |
|
| 1996 |
Ishizaki J, Nevins JR, Sullenger BA. Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function. Nature Medicine. 2: 1386-1389. PMID 8946842 DOI: 10.1038/Nm1296-1386 |
0.447 |
|
| 1996 |
Lee SW, Sullenger BA. Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. The Journal of Experimental Medicine. 184: 315-24. PMID 8760785 DOI: 10.1084/Jem.184.2.315 |
0.368 |
|
| 1996 |
Jones JT, Lee S, Sullenger BA. Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells. Nature Medicine. 2: 643-648. PMID 8640554 DOI: 10.1038/Nm0696-643 |
0.432 |
|
| 1995 |
Doudna JA, Cech TR, Sullenger BA. Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proceedings of the National Academy of Sciences of the United States of America. 92: 2355-9. PMID 7534420 DOI: 10.1073/Pnas.92.6.2355 |
0.375 |
|
| 1995 |
Sullenger BA. Colocalizing ribozymes with substrate RNAs to increase their efficacy as gene inhibitors. Applied Biochemistry and Biotechnology. 54: 57-61. PMID 7486985 DOI: 10.1007/Bf02787911 |
0.407 |
|
| 1994 |
Sullenger BA, Cech TR. Ribozyme-mediated repair of defective mRNA by targeted trans-splicing Nature. 371: 619-622. PMID 7935797 DOI: 10.1038/371619A0 |
0.41 |
|
| 1993 |
Sullenger BA, Cech TR. Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science (New York, N.Y.). 262: 1566-9. PMID 8248806 DOI: 10.1126/Science.8248806 |
0.381 |
|
| 1991 |
Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation Journal of Virology. 65: 6811-6816. PMID 1942253 DOI: 10.1128/Jvi.65.12.6811-6816.1991 |
0.405 |
|
| 1990 |
Sullenger BA, Lee TC, Smith CA, Ungers GE, Gilboa E. Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to moloney murine leukemia virus replication Molecular and Cellular Biology. 10: 6512-6523. PMID 2247070 DOI: 10.1128/Mcb.10.12.6512 |
0.372 |
|
| Show low-probability matches. |